Richards, Donald

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

Wang-Gillam, A., Li, C.-P., Bodoky, G., Dean, A., Shan, Y.-S., Jameson, G., Macarulla, T., Lee, K.-H., Cunningham, D., Blanc, J. F., et al. (2016) · The Lancet

Pancreatic and Hepatic Oncology ResearchCancer Treatment and Pharmacology

Cited by 1,222

Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study

Strickler, J. H., Cercek, A., Siena, S., André, T., Ng, K., Van Cutsem, E., Wu, C., Paulson, A. S., Hubbard, J. M., Coveler, A. L., et al. (2023) · The Lancet Oncology

Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research

Cited by 259

LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial

Golan, T., Geva, R., Richards, D., Madhusudan, S., Lin, B. K., Wang, H. T., Walgren, R. A., & Stemmer, S. M. (2018) · Journal of Cachexia, Sarcopenia and Muscle

Pancreatic and Hepatic Oncology ResearchNutrition and Health in Aging

Cited by 109

Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): a randomised, open-label phase II study

O'Shaughnessy, J., Sousa, S., Cruz, J., Fallowfield, L., Auvinen, P., Pulido, C., Cvetanovic, A., Wilks, S., Ribeiro, L., Burotto, M., et al. (2021) · European Journal of Cancer

HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes

Cited by 83

A phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancer

COHN, A., LAHN, M. M., WILLIAMS, K. E., CLEVERLY, A. L., PITOU, C., KADAM, S. K., FARMEN, M. W., DESAIAH, D., RAJU, R., CONKLING, P., et al. (2014) · International Journal of Oncology

TGF-β signaling in diseasesMonoclonal and Polyclonal Antibodies Research

Cited by 43

A Phase 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas Cancer

Muscarella, P., Bekaii-Saab, T., McIntyre, K., Rosemurgy, A., Ross, S. B., Richards, D. A., Fisher, W. E., Flynn, P. J., Mattson, A., Coeshott, C., et al. (2021) · Journal of Pancreatic Cancer

Pancreatic and Hepatic Oncology ResearchImmunotherapy and Immune Responses

Cited by 24

A phase Ib/II study of cancer stemness inhibitor napabucasin (BB608) combined with weekly paclitaxel in platinum-resistant ovarian cancer

Garcia, A. A., Hays, J. L., Cote, G. M., Becerra, C., Langleben, A., Lau, S. K., Roman, L. D., McCormick, C. C., Richards, D. A., Braiteh, F. S., et al. (2016) · Journal of Clinical Oncology

Ovarian cancer diagnosis and treatmentPARP inhibition in cancer therapy

Cited by 7